,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ghcg ,march #e1 #bjbf ,mr4 ,meuser introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xi of the ,social ,security ,act to require the ,center for ,medicare and ,medicaid ,innovation to test a model implementing most-favored-nation drug pricing4 #a4 ,short title ,this ,act may be cited as the ,most ,favored ,patient ,act of #bjbf4 #b4 ,requiring the ,center for ,medicare and ,medicaid ,innovation to test a model implementing most favored nation drug pricing ,section #aaae;,a of the ,social ,security ,act 7#db ,u4,s4,c4 #acae;a7 is amended-- 7#a7 in subsection 7b77#b77;,a71 by inserting 1 and1 beginning ,january #a1 #bjbi1 shall include the ,most ,favored ,nations ,pricing ,model described in subsection 7h7 before the period at the end2 and 7#b7 by adding at the end the following new subsection3 7h7 ,most ,favored ,nations ,pricing ,model 7#a7 ,in general ,for purposes of subsection 7b77#b77;,a71 the ,most ,favored ,nations ,pricing ,model described in this subsection is a model under which1 subject to paragraph 7#b71 each specified manufacturer-- 7,a7 provides access to the most-favored-nation price of each covered drug of such manufacturer-- 7i7 to most-favored-nation price eligible individuals who with respect to such drug are described in clause 7i7 of paragraph 7#e77;,d7 and are dispensed such drug 7and to pharmacies1 mail order services1 and other dispensers1 with respect to such individuals who are dispensed such drugs72 and 7ii7 to hospitals1 physicians1 and other providers of services and suppliers with respect to most-favored-nation price eligible individuals who with respect to such drug are described in clause 7ii7 of such paragraph furnished or administered such drug2 and 7,b7 reports to the ,secretary1 at such time and in such manner as the ,secretary shall specify1 such information as the ,secretary determines necessary for purposes of calculating the most-favored-nation price with respect to each such covered drug4 7#b7 ,exception ,the ,secretary may suspend the requirements under paragraph 7#a7 with respect to a covered drug of a specified manufacturer until ,april #a1 #bjbi1 if the ,secretary reasonably believes that such manufacturer is likely to enter into a covered agreement with the ,secretary before such date4 7#c7 ,duration ,the model described in paragraph 7#a7 shall be carried out for a period of #e years4 7#d7 ,definitions ,in this subsection3 7,a7 ,applicable net price ,the term applicable net price means1 with respect to a covered drug and a reference country in which such drug was sold during a year1 the average price paid to the manufacturer for the drug across package sizes and package types of the drug in such reference country during such year across all purchasers1 taking into account all manufacturer rebates1 discounts1 and price concessions1 and adjusted to take into account differences in purchasing power in such country compared to the ,united ,states in a manner specified by the ,secretary4 7,b7 ,appropriate congressional committees ,the term appropriate congressional committees means-- 7i7 the ,committee on ,energy and ,commerce and the ,committee on ,ways and ,means of the ,house of ,representatives2 and 7ii7 the ,committee on ,finance and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate4 7,c7 ,covered agreement ,the term covered agreement means an agreement between a manufacturer of a covered drug and the ,secretary that-- 7i7 provides that such manufacturer-- 7,i7 will provide access to the most-favored-nation price of #a or more covered drugs of such manufacturer in the same manner as described in paragraph 7#a77;,a72 7,,ii7 will report to the ,secretary the information described in paragraph 7#a77;,b7 with respect to each such drug2 and 7,,iii7 commits1 to the satisfaction of the ,secretary1 to increasing manufacturing operations in the ,united ,states2 and 7ii7 is-- 7,i7 entered into not later than ,december #ca1 #bjbh2 and 7,,ii7 reported by the ,secretary to the appropriate congressional committees-- 7aa7 not later than ,april #a1 #bjbi2 or 7bb7 in the case that such agreement was entered into before the date of the enactment of the ,most ,favored ,patient ,act of #bjbf1 not later than the date that is #cj days after such date of enactment4 7,d7 ,covered drug ,the term covered drug means1 with respect to a year1 a specified drug that was sold in #b or more reference countries during such year4 7,e7 ,manufacturer ,the term manufacturer has the meaning given such term in section #ahdg;,a7c77#f77;,a74 7,f7 ,most-favored-nation price ,the term most-favored-nation price means1 with respect to a covered drug and a year1 the second-lowest applicable net price for such drug4 7,g7 ,most-favored-nation price eligible individual ,the term most-favored-nation price eligible individual means1 with respect to a covered drug-- 7i7 in the case such drug is dispensed to the individual at a pharmacy1 by a mail order service1 or by another dispenser1 an individual-- 7,i7 who is eligible for medical assistance under a ,state plan 7or a waiver of such plan7 under title ,,xix if coverage is provided under such plan 7or waiver7 for such covered drug2 or 7,,ii7 who is enrolled in a prescription drug plan under part ,d of title ,,xviii or an ,,ma-,,pd plan under part ,c of such title if coverage is provided under such plan for such covered drug2 and 7ii7 in the case such drug is furnished or administered to the individual by a hospital1 physician1 or other provider of services or supplier1 an individual who is enrolled under part ,b of title ,,xviii1 including an individual who is enrolled in an ,,ma plan under part ,c of such title1 if payment may be made under part ,b for such selected drug4 7,h7 ,reference country ,the term reference country means any of the following countries3 7i7 ,canada4 7ii7 ,denmark4 7iii7 ,france4 7iv7 ,germany4 7v7 ,italy4 7vi7 ,japan4 7vii7 ,switzerland4 7viii7 ,the ,united ,kingdom4 7,i7 ,specified drug ,the term specified drug means-- 7i7 a covered outpatient drug 7as defined in section #aibg7k772 7ii7 a drug or biological product for which payment may be made under part ,b of title ,,xviii2 or 7iii7 a covered part ,d drug 7as defined in section #ahfj;,d-#b7;e774 7,j7 ,specified manufacturer ,the term specified manufacturer means a manufacturer of a covered drug that does not have a covered agreement with the ,secretary4 4